000516 Xi'An International Medical Investment
- 6.03
- -0.21-3.37%
Xi'An International Medical Investment News
International Medicine (000516): Continued expansion of business scale and gradual improvement of profitability
Investment highlights Revenue growth in 2023 is impressive, and profitability is expected to gradually improve: in 2023, the company achieved revenue of 4.618 billion yuan (+70.34%, an increase of 70.34% over the same period last year, same below), and net profit to mother
International Medicine (000516): Continued improvement in performance is expected to accelerate the reversal of losses throughout the year
Incident: The company released its 2023 annual report and quarterly report: achieved revenue of 4.618 billion yuan (+70.3%) in 2023; net profit to mother and net profit lost 3.68 billion yuan and 499 million yuan respectively, and losses narrowed by 600 million yuan year-on-year
International Medicine (000516) Company Brief Review Report: Continued expansion of business scale is expected to accelerate profitability
Investment highlights 2023: Rapid growth in performance, slightly exceeding expectations. The company released the 2023 report and the 2024 quarterly report: in 2023, it achieved revenue of 4.618 billion yuan, an increase of 70.3% over the previous year; net profit attributable to mother and net profit deducted from non-parent
International Medicine (000516): Performance is in line with expectations and continues to accumulate strength
Performance summary: The company released the 2024 quarterly report and the 2023 annual report. In the first quarter of 2024, revenue of 1.17 billion yuan (+10.8%) was achieved, net profit attributable to mother - 110 million yuan (-40.4%), after deduction
International Medicine (000516.SZ): Net profit for the first quarter - $105 million
On April 25, Ge Longhui (000516.SZ) released its report for the first quarter of 2024, achieving operating income of 1,173 billion yuan, an increase of 10.75% over the previous year; net profit attributable to shareholders of listed companies - 105 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 898.496 million yuan, basic earnings per share - 0.0464 yuan.
Published 2 articles in a row in the top international medical journal “The Lancet”, a team from Jiangsu is expected to rewrite the international treatment guidelines for coronary heart disease
Recently, two groundbreaking research results carried out by Professor Chen Shaoliang's team from the Department of Cardiovascular Medicine at Nanjing First Hospital were published in the official issue of the top international medical journal “The Lancet”. These two clinical practices from China have provided China's solutions for interventional treatment of coronary heart disease in the world, expanded the international influence of coronary heart disease clinical research in China, and will fill the gaps in Chinese and Western cardiovascular treatment guidelines. The reporter learned that both studies revolved around a serious coronary heart disease — acute coronary syndrome.
International Medicine (000516) In-depth Research Report: The time is right for a regional comprehensive medical service leader to take off
Through transformation, a high-level, research-based, and multi-level comprehensive medical service platform has taken shape. Adhering to the tenet of “protecting the immeasurable value”, with the innovative business model of “comprehensive medical+special specialties”, the infrastructure of international medicine has now become a whole life
International Medicine (000516.SZ): Chairman, Vice Chairman and all executives increased their holdings by a total of 537,900 shares
Gelonghui, Feb. 2 | International Medicine (000516.SZ) announced that the company received notifications from the chairman, vice chairman and all senior management of the company to learn that the company's chairman, Ms. Shi Jin, Vice Chairman, Ms. Wang Aiping, Director and President Mr. Liu Ruixuan, Director and Vice President, Mr. Sun Wenguo, Vice President and Board Secretary, Mr. Wang Yu, Vice President, Mr. Sun Yikuan, Vice President, and Ms. Wang Yaxing increased the company's shares by centralized bidding through the Shenzhen Stock Exchange trading system from January 31 to February 2, 2024, accounting for Total share capital of the company 2,260
International Medicine (000516): High revenue growth in 2023Q4, steady profits, and 2024 is expected to usher in a profit inflection point
Key Investment Highlights On January 30, the company released its 2023 performance forecast: estimated revenue of 4.61585-4.658.5 billion yuan in 2023 (year-on-year increase of 70.27%-71.74%), net return to mother
International Medicine (000516): Operating losses narrowed month-on-month in the fourth quarter, revenue climbed and business trends improved in 23 years
Key investment events: The company announced that in 2023, the company achieved operating income of 4.616 to 4.656 billion yuan, and net revenue of 4.45 to 4.48 billion yuan. The company expects to achieve a net profit loss of 2.8-3 to the mother.
International Medicine (000516.SZ) issued a forecast loss. The net loss for 2023 is expected to be 280 million yuan to 370 million yuan
International Medicine (000516.SZ) announced its 2023 annual results forecast, which is expected to be owned by shareholders of listed companies for the whole year...
International Medicine (000516): In 4Q23, revenue increased again in a single quarter, and the volume of inpatient services continued to increase
Incident: January 30, 2024, the company released its 2023 performance forecast. The annual revenue was 4.62 billion yuan to 4.65 billion yuan, an increase of 70.4% to 71.5% over the previous year; net loss to mother was 280 million yuan to 370 million yuan.
International Medicine (000516.SZ): The company's three major comprehensive medical hospitals currently have 10,137 planned beds, and currently the number of beds in use exceeds 5,000
On December 29, Ge Longhui | International Medicine (000516.SZ) said on the investor interactive platform that after years of exploration, international medicine has developed an innovative “comprehensive medical+specialty” business model, fully relying on existing Level 3 A and international JCI certification. Miaoyou Medical Alliance member hospitals provide a full-life cycle medical and health service platform to provide high-quality comprehensive medical services to patients to meet diverse medical and health needs. The company's three comprehensive medical hospitals currently have 10,137 planned beds. Currently, the number of beds in use exceeds 5,000, according to the company's latest five-year development regulations
The A-share brain-computer interface sector fluctuated and rose
Gelonghui, December 11 | Nanjing Pandas rose more than 5%, and International Medicine, Yingqu Technology, Jiahe Intelligence, Oriental Medicine, and Xiangyu Medical followed suit.
International Medicine (000516.SZ): In the third quarter, its medical institutions added 23 new hospitals cooperating with the Medical Federation
On November 16, Gelonghui International Medicine (000516.SZ) recently stated during a survey of institutional investors that in the third quarter of 2023, the company's medical institutions added 23 new hospitals cooperating with the medical consortium; the proportion of overseas patients in high-tech hospitals reached 31.31%; the proportion of overseas patients in central hospitals reached 37.93%, and the proportion of overseas patients in the company's medical institutions continued to grow.
International Medicine (000516.SZ): The proton therapy center is currently being built and is expected to be put into use in 2025
Gelonghui, November 16|International Medicine (000516.SZ) recently stated during a survey from institutional investors that construction of the proton therapy center is currently being accelerated. Due to its long construction period, it is expected to be put into use in 2025.
International Medicine (000516.SZ): Xi'an Gaoxin Hospital has the highest number of daily use of more than 1,700 beds
On November 16, Gelonghui International Medicine (000516.SZ) stated at an investor relations event that the number of inpatient services in the company's medical institutions is constantly increasing. Recently, the number of beds used on the highest day in the north-south campus of Xi'an International Medical Center Hospital reached more than 3,700, and the number of beds used on the highest day in Xi'an High-tech Hospital reached more than 1,700.
International Medicine (000516): Continued optimization of asset structure may usher in a loss-turning point
Investment Highlights Recently, International Medicine released its three-quarter report for 2023. In the first three quarters of 2023, the company achieved operating income of 3,344 billion yuan, an increase of 74.70% over the previous year; realized net profit of 222 million yuan; actual
The hyperbaric oxygen tank sector boosted the rise of innovative medical treatment
Gelonghui November 9 | Innovative Healthcare Seals Rise and Stop, and International Medicine, Samsung Healthcare, and Weiao Shares have followed suit.
Research Report Nuggets: Southwest Securities: Maintaining the International Medical “Buy” Rating, Target Price: 13.29 Yuan
Gelonghui, November 6 | According to the Southwest Securities Research Report, international medicine (000516.SZ) focuses on core hospitals to create a highland of medical services in the northwest. The Xi'an High-tech Hospital under the company is the first top three social medical hospital in China, with 1,500 open beds; Xi'an International Medical Center Hospital is a tertiary general hospital built according to the top three standards, with a planned capacity of 5037 beds. The two major core hospitals can reduce the current shortage of high-quality medical resources in the central and western regions. On the other hand, the company actively lays out fields such as medical aesthetics, rehabilitation medicine, and assisted reproduction. The business structure will continue to be optimized, and the company is working hard to set sail. The bank expects 2
Analysis
Price Target
No Data
